{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:39:11Z","timestamp":1792402751134,"version":"4.4.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":3035,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1093\/annonc\/mdq677","type":"journal-article","created":{"date-parts":[[2011,2,22]],"date-time":"2011-02-22T03:44:13Z","timestamp":1298346253000},"page":"1859-1864","source":"Crossref","is-referenced-by-count":130,"title":["Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt's lymphoma: a retrospective analysis"],"prefix":"10.1016","volume":"22","author":[{"given":"J.A.","family":"Barnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Toomey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Michaelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq677_bb0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdq677_bb0015","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq677_bb0020","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq677_bb0025","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdq677_bb0030","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq677_bb0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","article-title":"High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients","volume":"113","author":"Oriol","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq677_bb0040","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/cncr.11628","article-title":"Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate\/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M\/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma","volume":"98","author":"Wang","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq677_bb0045","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/cncr.10365","article-title":"Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma\/leukemia","volume":"94","author":"Cortes","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq677_bb0050","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq677_bb0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq677_bb0060","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq677_bb0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq677_bb0070","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq677_bb0075","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq677_bb0080","first-page":"2736","article-title":"Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: preliminary results showing excellent outcome","volume":"108","author":"Dunleavy","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1093\/annonc\/mdq677_bb0085","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","article-title":"Update of the M.D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas","volume":"8","author":"Fayad","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdq677_bb0090","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq677_bb0095","series-title":"WHO Classification of Tumours of Haematopoetic and Lymphoid Tissue","author":"Swerdlow","year":"2008"},{"key":"10.1093\/annonc\/mdq677_bb0100","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419383899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419383899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/8\/1859\/19481462\/mdq677.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T05:13:47Z","timestamp":1624684427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419383899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0923753419383899"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq677","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.9023959.9917054","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}